Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result
NCT00146120Phase 3Completed
- Sponsor
- Ulm University
- Start
- May 1998
- Primary completion
- May 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of idarubicin, cytarabine, etoposide and tretinoin in acute myeloid leukemia (AML) (3 arms), sponsored by Ulm University. Primary endpoint: Relapse-Free Survival at 2 years. Started May 1998; status: completed.
02
Drugs
idarubicincytarabineetoposidetretinoin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00146120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00146120.